By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...
Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy ...
The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...
SurvivorNet on MSN
ASCO 2026: A major prostate cancer trial shows drug can keep high-risk disease from returning for longer
Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...
Aglatimagene is an investigational therapy that uses a modified virus to deliver a cancer-fighting gene into tumor cells.
Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...
Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with ...
Dr. Glenn Bauman, Scientist at LHSCRI and Radiation Oncologist at London Health Sciences Centre (LHSC), stands in front of the positron emission tomography (PET) scanner. LONDON, ON – A multicentre ...
Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAdditionConsistent ...
Researchers at Columbia University Irving Medical Center have identified a gene that drives the development of neuroendocrine ...
How much do healthy lifestyle habits, such as diet and exercise, matter after a cancer diagnosis? Adopting healthy lifestyle ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results